SpringerLink
Log in

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish lung cancer group GECP. Controversies and discussion

  • CORRESPONDENCE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

The Original Article was published on 26 March 2024

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ospina AV, Bolufer Nadal S, De La Campo-Cañaveral Cruz JL, González Larriba JL, Macía Vidueira I, Massutí Sureda B, Nadal E, Trancho FH, Álvarez Kindelán A, Del Barco Morillo E, Bernabé Caro R, Bosch Barrera J, De Calvo Juan V, Casal Rubio J, De Castro J, Cilleruelo Ramos Á, Cobo Dols M, Dómine Gómez M, Figueroa Almánzar S, Garcia Campelo R, Insa Mollá A, Jarabo Sarceda JR, Jiménez Maestre U, López Castro R, Majem M, Martinez-Marti A, Martínez Téllez E, Sánchez Lorente D, Provencio M. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Clin Transl Oncol. 2024. https://doi.org/10.1007/s12094-024-03382-y.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Dickhoff C, Heineman D, Schneiders F, Houda I, Veltman J, Hashemi S, Fransen M, Radonic T, Bartelink I, Meijboom L, Oprea-Lager D, Bouwhuis N, De Gruijl T, Senan S, Bahce I. OA06.04 surgery after neoadjuvant immuno-chemoradiotherapy in (borderline) Resectable NSCLC: results from the INCREASE Trial. J Thorac Oncol. 2023;18:S56–7. https://doi.org/10.1016/j.jtho.2023.09.045.

    Article  Google Scholar 

  3. Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur W-D, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39:2872–80. https://doi.org/10.1200/JCO.21.00276.

    Article  CAS  Google Scholar 

  4. Dickhoff C, Heineman DJ, Bahce I, Senan S. Unresectable stage III NSCLC can be reevaluated for resectability after initial treatment. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2023;18:1124–8. https://doi.org/10.1016/j.jtho.2023.06.002.

    Article  Google Scholar 

  5. Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2023;18:181–93. https://doi.org/10.1016/j.jtho.2022.10.003.

    Article  CAS  Google Scholar 

  6. Houda I, Dickhoff C, Uyl-de Groot CA, Damhuis RAM, Reguart N, Provencio M, Levy A, Dziadziuszko R, Pompili C, Di Maio M, Thomas M, Brunelli A, Popat S, Senan S, Bahce I. Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective. Lancet Reg Health Eur. 2024;38:100841. https://doi.org/10.1016/j.lanepe.2024.100841.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Institut Català d’Oncologia, Barcelona, Spain

    Arturo Navarro Martín

  2. Department of Radiation Oncology, Complejo Hospitalario Universitario Orense, Orense, Spain

    Nuria Rodriguez de Dios

  3. Department of Radiation Oncology, University Hospital Virgen del Rocío, Manuel Siurot Avenue, S/N. 41013, Seville, Spain

    Jose Luis Lopez Guerra

  4. Genesiscare-Hospital Universitario San Francisco de Asís y Vithas Madrid La Milagrosa, Madrid, Spain

    Felipe Couñago Lorenzo

Authors
  1. Arturo Navarro Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nuria Rodriguez de Dios
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose Luis Lopez Guerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Felipe Couñago Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jose Luis Lopez Guerra.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Navarro Martín, A., Rodriguez de Dios, N., Lopez Guerra, J. et al. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish lung cancer group GECP. Controversies and discussion. Clin Transl Oncol (2024). https://doi.org/10.1007/s12094-024-03540-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12094-024-03540-2

Search

Navigation